# US 2016/0257652 A1 · Antidiabetic tricyclic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257652 A1
- Document ID: US20160257652A1
- Status: Published application
- Kind: A1
- Application number: 15/032,191
- Filed: 2014-11-10
- Published: 2016-09-08
- Earliest claimed: 2013-11-15
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: Tesfaye Biftu; Purakkattle Biju; Steven L. Colletti; Qun Dang; Pawan Dhondi; Candido Gude; Hubert Josien; Nam Fung Kar; Anilkumar G. Nair; Ravi P. Nargund; De-Yi Yang; Cheng Zhu
- Web page: https://patentgrep.com/patent/US20160257652A1

## CPC

- C07D 221/16: containing carbocyclic rings other than six-membered
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 31/435: having six-membered rings with one nitrogen as the only ring hetero atom
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 487/04: Ortho-condensed systems
- C07D 487/10: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

## Claims

### Claim 1

A compound of structural formula I:
or a pharmaceutically acceptable salt thereof; wherein
A is phenyl;
B is selected from the group consisting of:
(1) phenyl, and
(2) pyridyl;
R1 is selected from the group consisting of:
(1) halogen,
(2) —CN,
(3) —C1-6alkyl,
(4) —(CH2)rOC1-6alkyl,
(5) —(CH2)r—C3-6cycloalkyl, and
(6) —(CH2)r—O—(CH2)—C3-6cycloalkyl,
wherein each CH2, —C1-6alkyl, —OC1-6alkyl and C3-6cycloalkyl is unsubstituted or substituted with one to four substituents selected from halogen, —C1-6alkyl and —(CH2)v—C3-6cycloalkyl;
R2 is halogen;
each R3 when present is independently selected from the group consisting of:
(1) halogen,
(2) —CN,
(3) —C1-6alkyl, and
(4) —(CH2)—C3-6cycloalkyl,
wherein each CH2, C1-6alkyl and C3-6cycloalkyl is unsubstituted or substituted with one to three substituents selected from halogen;
R4 is selected from the group consisting of:
(1) —(CH2)pC3-6cycloalkyl,
(2) —O(CH2)pC3-6cycloalkyl,
(3) —(CH2)p—C2-10cycloheteroalkyl,
(4) —O(CH2)p—C2-10cycloheteroalkyl,
(5) aryl, and
(6) heteroaryl,
wherein R4 is unsubstituted or substituted with one, two, three, four or five substituents selected from R5;
R5 is selected from the group consisting of:
(1) —(CH2)shalogen,
(2) —C1-6alkyl,
(3) —(CH2)s—O—C1-6alkyl,
(4) —(CH2)sOH,
(5) —(CH2)sCN,
(6) —(CH2)sSO2C1-6alkyl,
(7) —(CH2)sSO2—(CH2)t—C3-6cycloalkyl,
(8) —CF3,
(9) —OCHF2,
(10) —OCF3,
(11) —SCH3,
(12) —NH2,
(13) oxo,
(14) —NHSO2C1-6alkyl,
(15) —NHCOC1-6alkyl,
(16) —NH(C1-6alkyl), and
(17) —N(C—6alkyl)2,
wherein each CH2, C1-6alkyl and C3-6cycloalkyl is unsubstituted or substituted with one to three substituents selected from halogen, C1-6alkyl, and —(CH2)wOH;
m is 0, 1, 2 or 3;
n is 1 or 2;
p is 0, 1, 2, 3 or 4;
r is 0, 1, 2 or 3;
s is 0, 1, 2 or 3;
t is 0, 1, 2 or 3;
u is 0, 1, 2 or 3;
v is 0, 1, 2 or 3; and
w is 0, 1, 2 or 3.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein A is:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound according to claim 1 wherein A is
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound according to claim 1 wherein B is phenyl, wherein phenyl is unsubstituted or substituted with one, two or three substituents selected from R3;
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound according to claim 1 wherein B is pyridyl, wherein pyridyl is unsubstituted or substituted with one, two or three substituents selected from R3; or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound according to claim 1 wherein R1 is selected from the group consisting of:
(1) halogen,
(2) —CN,
(3) —C1-6alkyl, and
(4) —(CH2)rOC1-6alkyl,
wherein each CH2, —C1-6alkyl and —OC1-6alkyl is unsubstituted or substituted with one to four substituents selected from halogen, and —C1-6alkyl; or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The compound according to claim 1 wherein R1 is selected from the group consisting of:
(1) halogen,
(2) —CN, and
(3) —C1-6alkyl,
wherein each —C1-6alkyl is unsubstituted or substituted with one to four substituents selected from halogen, and —C1-6alkyl; or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The compound according to claim 1 wherein R1 is selected from the group consisting of:
(1) —CN,
(2) —C1-6alkyl, and
(3) —(CH2)—C3-6cycloalkyl,
wherein each CH2, —C1-6alkyl and —C3-6cycloalkyl is unsubstituted or substituted with one to four substituents selected from halogen, and —C1-6alkyl; or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

The compound according to claim 1 wherein R1 is halogen, or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The compound according to claim 1 wherein R2 is F; or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

The compound according to claim 1 wherein each R3 when present is independently selected from the group consisting of:
(1) halogen, and
(2) —C1-6alkyl,
wherein each C1-6alkyl is unsubstituted or substituted with one to three substituents selected from halogen; or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

The compound according to claim 1 wherein R4 is selected from the group consisting of:
(1) —O(CH2)pC3-6cycloalkyl,
(2) —C2-6cycloheteroalkyl,
(3) aryl, and
(4) heteroaryl,
wherein R4 is unsubstituted or substituted with one, two, three, four or five substituents selected from R5; or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The compound according to claim 1 wherein R4 is selected from the group consisting of:
(1) —O(CH2)pC3-6cycloalkyl,
(2) —C2-8cycloheteroalkyl, and
(3) aryl,
wherein R4 is unsubstituted or substituted with one, two, three, four or five substituents selected from R5; or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The compound according to claim 1 wherein R4 is selected from the group consisting of:
(1) —O—CH2-cyclobutyl,
(2) —O-cyclohexyl,
(3) 2,6-diazospiro[3,3]heptan-2yl,
(4) piperidinyl, and
(5) phenyl,
wherein R4 is unsubstituted or substituted with one, two, three, four or five substituents selected from R5; or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The compound according to claim 1 wherein R5 is selected from the group consisting of:
(1) —(CH2)shalogen,
(2) —C1-6alkyl,
(3) —(CH2)sOH,
(4) —(CH2)sCN,
(5) —(CH2)sSO2C1-6alkyl, and
(6) —(CH2)sSO2—(CH2)t—C3-6cycloalkyl,
wherein each CH2, C1-6alkyl and C3-6cycloalkyl is unsubstituted or substituted with one to three substituents selected from halogen, C1-6alkyl, and —(CH2)wOH; or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

The compound according to claim 1 wherein R5 is selected from the group consisting of:
(1) —(CH2)shalogen,
(2) —C1-6alkyl,
(3) —(CH2)sOH,
(4) —(CH2)sSO2C1-6alkyl, and
(5) —(CH2)sSO2—(CH2)t—C3-6cycloalkyl,
wherein each CH2, C1-6alkyl and C3-6cycloalkyl is unsubstituted or substituted with one to three substituents selected from halogen, C1-6alkyl, and —(CH2)wOH; or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

The compound according to claim 1 wherein R5 is selected from the group consisting of:
(1) halogen,
(2) —C1-6alkyl,
(3) —OH,
(4) —SO2C1-6alkyl, and
(5) —SO2—C3-6cycloalkyl,
wherein each CH2, C1-6alkyl and C3-6cycloalkyl is unsubstituted or substituted with one to three substituents selected from halogen, C1-6alkyl, and —(CH2)wOH; or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

The compound according to claim 1 wherein the absolute stereochemistry at the two stereogenic carbon centers is indicated below:
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

The compound according to claim 1 wherein:
A is phenyl;
B is phenyl;
R1 is selected from the group consisting of:
(1) halogen,
(2) —CN,
(3) —C1-6alkyl, and
(4) —(CH2)r—OC1-6alkyl,
wherein each CH2, —C1-6alkyl and —OC1-6alkyl is unsubstituted or substituted with one to four substituents selected from halogen, and —C1-6alkyl;
R2 is halogen;
each R3 when present is independently selected from the group consisting of:
(1) halogen, and
(2) —C1-6alkyl,
wherein each C1-6alkyl is unsubstituted or substituted with one to three substituents selected from halogen;
R4 is selected from the group consisting of:
(1) —O(CH2)pC3-6cycloalkyl,
(2) —C2-6cycloheteroalkyl,
(3) aryl, and
(4) heteroaryl,
wherein R4 is unsubstituted or substituted with one, two, three, four or five substituents selected from R5;
R5 is selected from the group consisting of:
(1) —(CH2)shalogen,
(2) —C1-6alkyl,
(3) —(CH2)sOH,
(4) —(CH2)sCN,
(5) —(CH2)sSO2C1-6alkyl, and
(6) —(CH2)sSO2—(CH2)t—C3-6cycloalkyl,
wherein each CH2, C1-6alkyl and C3-6cycloalkyl is unsubstituted or substituted with one to three substituents selected from halogen, C1-6alkyl, and —(CH2)wOH;
m is 1; and
n is 1;
or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1)

The compound according to claim 1 wherein:
A is:
B is phenyl;
R1 is selected from the group consisting of:
(1) halogen,
(2) —CN, and
(3) —C1-6alkyl,
wherein each —C1-6alkyl is unsubstituted or substituted with one to four substituents selected from halogen, and —C1-6alkyl;
R2 is halogen;
each R3 when present is independently selected from the group consisting of:
(1) halogen, and
(2) —C1-6alkyl,
wherein each C1-6alkyl is unsubstituted or substituted with one to three substituents selected from halogen;
R4 is selected from the group consisting of:
(1) —O(CH2)pC3-6cycloalkyl,
(2) —C2-8cycloheteroalkyl, and
(3) aryl,
wherein R4 is unsubstituted or substituted with one, two, three, four or five substituents selected from R5;
R5 is selected from the group consisting of:
(1) —(CH2)shalogen,
(2) —C1-6alkyl,
(3) —(CH2)sOH,
(4) —(CH2)sSO2C1-6alkyl, and
(5) —(CH2)sSO2—(CH2)t—C3-6cycloalkyl,
wherein each CH2, C1-6alkyl and C3-6cycloalkyl is unsubstituted or substituted with one to three substituents selected from halogen, C1-6alkyl, and —(CH2)wOH; and
m is 1;
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

The compound according to claim 1 wherein
A is
B is phenyl;
R1 is selected from the group consisting of:
(1) halogen,
(2) —CN, and
(3) —C1-6alkyl,
wherein each —C1-6alkyl is unsubstituted or substituted with one to four substituents selected from halogen, and —C1-6alkyl;
R2 is F;
each R3 when present is independently selected from the group consisting of:
(1) halogen, and
(2) —C1-6alkyl,
wherein each C1-6alkyl is unsubstituted or substituted with one to three substituents selected from halogen;
R4 is selected from the group consisting of:
(1) —O—CH2-cyclobutyl,
(2) —O-cyclohexyl,
(3) 2,6-diazospiro[3,3]heptan-2yl,
(4) piperidine, and
(5) phenyl,
wherein R4 is unsubstituted or substituted with one, two, three, four or five substituents selected from R5;
R5 is selected from the group consisting of:
(1) halogen,
(2) —C1-6alkyl,
(3) —OH,
(4) —SO2C1-6alkyl, and
(5) —SO2—C3-6cycloalkyl,
wherein each CH2, C1-6alkyl and C3-6cycloalkyl is unsubstituted or substituted with one to three substituents selected from halogen, C1-6alkyl, and —(CH2)wOH; and
m is 1;
or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 1)

The compound according to claim 1 selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim at position 24

24-26. (canceled)

### Claim 27 (depends on 1)

A method of treating or preventing a disorder, condition or disease that is responsive to the agonism of the G-protein-coupled receptor 40 in a patient in need thereof comprising administration of a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 1)

A method of treating type 2 diabetes mellitus in a patient in need of treatment comprising the administration to the patient of a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 29 (depends on 1)

A pharmaceutical composition comprising
(1) a compound of claim 1, or a pharmaceutically acceptable salt thereof;
(2) one or more compounds selected from the group consisting of:
(a) PPAR gamma agonists and partial agonists;
(b) biguanides;
(c) protein tyrosine phosphatase-1B (PTP-1B) inhibitors;
(d) dipeptidyl peptidase IV (DP-IV) inhibitors;
(e) insulin or an insulin mimetic;
(f) sulfonylureas;
(g) α-glucosidase inhibitors;
(h) agents which improve a patient's lipid profile, said agents being selected from the group consisting of (i) HMG-CoA reductase inhibitors, (ii) bile acid sequestrants, (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PPARα agonists, (v) cholesterol absorption inhibitors, (vi) acyl CoA: cholesterol acyltransferase (ACAT) inhibitors, (vii) CETP inhibitors, and (viii) phenolic anti-oxidants;
(i) PPARα/γ dual agonists,
(j) PPARδ agonists,
(k) antiobesity compounds,
(l) ileal bile acid transporter inhibitors;
(m) anti-inflammatory agents;
(n) glucagon receptor antagonists;
(o) GLP-1;
(p) GIP-1;
(q) GLP-1 analogs;
(r) HSD-1 inhibitors;
(s) SGLT 1 inhibitors; and
(t) SGLT 2 inhibitors; and
(3) a pharmaceutically acceptable carrier.

### Claim 30 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a compound selected from simvastatin, ezetimibe and sitagliptin; and a pharmaceutically acceptable carrier.
